Stock ticker :
NYSE
ZTS
AS OF
Jan 21, 12:43 PM (EST)
Price
$202.63
Change
+$0.70 (+0.35%)
Capitalization
$95.6b
ZTS
Stock ticker :
NYSE
25 days until earnings call
Intraday data for
Jan 21, 12:43 PM (EST)
Price
$202.63
Change
+$0.70 (+0.35%)
Capitalization
$95.6b

(ZTS) Stock Forecast and AI Recommendations

a pet medication company
Industry PharmaceuticalsOther

ZOETIS (ZTS) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a pet medication company
Industry PharmaceuticalsOther
A.I.dvisor published
a Summary for ZTS with price predictions.
4:00 PM EST Jan 20

ZTS in downward trend: price dove below 50-day moving average on January 04, 2022

ZTS moved below its 50-day Moving Average on January 04, 2022 date and that indicates a change from an upward trend to a downward trend. In 17 of 47 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 36%.

Stock Forecast, Price, News, Quote

Current price $202.63 crossed the support line at $210.77 and is trading between $210.77 support and $196.37 support lines. Throughout the month of 12/17/21 - 01/20/22, the price experienced a -14% Downtrend. During the week of 01/12/22 - 01/20/22, the stock fell -5%.

Technical Analysis (Indicators)
Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 03, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ZTS as a result. In 29 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 34%.

The Moving Average Convergence Divergence Histogram (MACD) for ZTS turned negative on January 03, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 12 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 26%.

The 10-day Moving Average for ZTS crossed bearishly below the 50-day moving average on January 12, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 33%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 29%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 236 of 369 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

ZTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 226 of 353 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. ZTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.408) is normal, around the industry mean (6.545). P/E Ratio (48.780) is within average values for comparable stocks, (44.916). Projected Growth (PEG Ratio) (2.842) is also within normal values, averaging (2.542). ZTS has a moderately low Dividend Yield (0.005) as compared to the industry average of (0.019). P/S Ratio (12.658) is also within normal values, averaging (109.036).

The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

A.I.dvisor published
ZOETIS Earnings Data

ZTS is expected to report earnings to fall 22.06% to 97 cents per share on February 15

ZOETIS ZTS Stock Earnings Report
Q4'21
Est.
$0.97
Q3'21
Beat
by $0.14
Q2'21
Beat
by $0.10
Q1'21
Beat
by $0.22
Q4'20
Beat
by $0.05
The last earnings report on November 04 showed earnings per share of $1.25, beating the estimate of $1.11. With 183.85K shares outstanding, the current market capitalization sits at 95.55B.
A.I.dvisor found
ZOETIS Dividends
ZTS is expected to pay dividends on March 01, 2022
ZOETIS ZTS Stock Dividends
A dividend of $0.32 per share will be paid with a record date of March 01, 2022, and an ex-dividend date of January 19, 2022. The last dividend of $0.25 was paid on December 01. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Pharmaceuticals Generic
Address 10 Sylvan Way, Parsippany, NJ, 07054
Phone +1 973 822-7000
Employees 11300
Web https://www.zoetis.com
ZTS

Select Stock attributes to show

Capitalization 95.6B
P/E Ratio 48.78
Risk (Beta) 0.68
Dividend Yield 0.01
Total Cash 3.658B
Total Cash/Share 7.73
Total Debt 7.343B
Total Debt/Equity 332.85
Projected Growth (PEG Ratio) 2.84
Revenue/Share (as % of the share price) 16%
Revenue 7.412B
ROE N/A
Book Value 4.35B
P/B Ratio 20.41
Cash Flow N/A
Earnings 4.010
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 5M
Current Ratio 3.37
Current Revenue Per Employee 172,389.38
Dividends Per Share - Security 0.25
EBITDA 3.015B
Float N/A
Float - Current N/A
Gross Income Margin 70.84
Revenue To Assets 14.07
Shares Held By Institutions 1.283T
Shares Outstanding - Current N/A
Total Liabilities 9.717B
Total Volume MTD N/A
Value Over
Gain YTD -17.107
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 95.55b USD
P/E Ratio 48.780487
Total Cash 3.66b USD
Projected Growth 2.84
Total Debt 7.34b USD
Revenue 7.41b USD
Risk (Beta) 0.68
Dividend Yield 0.01
Total Cash/Share 7.73
Total Debt/Equity 332.85
Revenue/Share 16.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD